TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18685945

Group type: EXPERIMENTAL
Intervention: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.01 mg x kg(‐1) x min(‐1)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.02 mg x kg(‐1) x min(‐1)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.03 mg x kg(‐1) x min(‐1)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.04 mg x kg(‐1) x min(‐1)
Number of subjects: 59
Study: 16573799

Group type: EXPERIMENTAL
Intervention: Lactulose (single dose)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Lactulose (long-term administration)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Saccharomyces boulardii
Number of subjects: 43
Study: 15339557

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) and traditional Chinese medicine (TCM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 39
Study: 10712318

Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin (7.5 mg/kg every 8 h)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Vancomycin (1 g every 12 h)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin
Number of subjects: 298

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 298
Study: 8757574

Group type: EXPERIMENTAL
Intervention: Fentanyl infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study: 1388662

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 108
Study: 3895289

Group type: EXPERIMENTAL
Intervention: Iopamidol (250 mg I/ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ioxithalamate (250 mg I/ml)
Number of subjects: 40
Study: 29531280

Group type: EXPERIMENTAL
Intervention: Enhanced Normative Feedback and Cognitive Bias Re‐training
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Enhanced Self‐monitoring and Feedback and Action Planning
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Enhanced Self‐monitoring and Feedback
Number of subjects: 672

Group type: COMPARATOR
Intervention: Minimal version of app modules
Number of subjects: 672
Study: 29424509

Group type: EXPERIMENTAL
Intervention: Hydrodissection with epinephrine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-hydrodissection
Number of subjects: 44
Study: 25064769

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 83
Study: 22379745

Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg thrice daily plus omeprazole 20 mg twice daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 70
Study: 20058059

Group type: EXPERIMENTAL
Intervention: Children's Friendship Training (CFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC)
Number of subjects: 0
Study: 18502357

Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol 300 mg orally 5 to 6 hours before surgery
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 66
Study: 16005690

Group type: EXPERIMENTAL
Intervention: Clobazam (10mg oral dose)
Number of subjects: 0
Study: 12453950

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 10362210

Group type: EXPERIMENTAL
Intervention: Hormone replacement (0.625 mg/day conjugated equine estrogens and 2.5 mg/day medroxyprogesterone acetate)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hormone replacement plus lovastatin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 24
Study: 8964637

Group type: EXPERIMENTAL
Intervention: Variable Kd (gradual and constant elimination of K+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kd 2 mEq/l (standard potassium removal)
Number of subjects: 0
Study: 2167702

Group type: COMPARATOR
Intervention: VAC (vincristine 1 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 750 mg/m2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: VACE (vincristine 1 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 750 mg/m2, etoposide 80 mg/m2 for 3 days)
Number of subjects: 80
Study: 7025960

Group type: EXPERIMENTAL
Intervention: Natural evacuation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Colostomy irrigation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Foam enema
Number of subjects: 20

Group type: COMPARATOR
Intervention: Colostomy irrigation and foam enema
Number of subjects: 20
Study: 31182351

Group type: EXPERIMENTAL
Intervention: Nabilone (target 1–2 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 39
Study: 29086911

Group type: COMPARATOR
Intervention: 50 μg phenylephrine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 7.5 mg ephedrine
Number of subjects: 42
Study: 27550914

Group type: EXPERIMENTAL
Intervention: Less tight control (target diastolic 100 mm Hg)
Number of subjects: 981

Group type: COMPARATOR
Intervention: Tight control (target diastolic 85 mm Hg)
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Less tight control
Number of subjects: 981

Group type: COMPARATOR
Intervention: Tight control
Number of subjects: 981
Study: 25017670

Group type: EXPERIMENTAL
Intervention: Chronic electrical epidural stimulation of the auditory cortex
Number of subjects: 9
Study: 21818820

Group type: EXPERIMENTAL
Intervention: Intra-arterial (IA) chemoradiotherapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intravenous (IV) chemoradiotherapy
Number of subjects: 71
Study: 20828648

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg)
Number of subjects: 18597

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18597
Study: 18041059

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 19818

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 19818
Study: 15807183

Group type: EXPERIMENTAL
Intervention: Off-pump technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: On-pump technique
Number of subjects: 60
Study: 12701762

Group type: EXPERIMENTAL
Intervention: Randomized children (n = 270)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Eligible children whose parents immediately refused participation (n = 243)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Eligible children whose parents were informed but did not consent (n = 406)
Number of subjects: 270
Study: 10370919

Group type: EXPERIMENTAL
Intervention: Augmented feedback condition
Number of subjects: 91

Group type: COMPARATOR
Intervention: Sensory feedback condition
Number of subjects: 91
Study: 8957977

Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Suxamethonium-Mivacurium combination
Number of subjects: 100

Group type: COMPARATOR
Intervention: Suxamethonium-Atracurium combination
Number of subjects: 100
Study: 1677062

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Other vitamins (A,D,B1,B2,B6,C and nicotinamide)
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Both folic acid and other vitamins
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Neither folic acid nor other vitamins
Number of subjects: 1817
Study: 6832465

Group type: EXPERIMENTAL
Intervention: Dithranol cream 0.25%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dithranol stylus 0.2%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dithranol cream 0.25% and Dithranol stylus 0.2%
Number of subjects: 60
Study: 30638644

Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil 0.7 μg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous morphine 0.1 mg/kg
Number of subjects: 60
Study: 28413993

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus oral weight based ribavirin for 24 weeks
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus oral weight based ribavirin and a 180 mcg Peg‐INF alpha 2a subcutaneous injection weekly for 12 weeks
Number of subjects: 200
Study: 25994549

Group type: EXPERIMENTAL
Intervention: FLU-v (500 μg) and the adjuvant
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (adjuvant alone)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: FLU-v
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 24491069

Group type: EXPERIMENTAL
Intervention: FFT followed by CWD (FFT/CWD)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: CWD followed by FFT (CWD/FFT)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Coordinated FFT and CWD (CT)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: All treatment sequences
Number of subjects: 170
Study: 23220732

Group type: EXPERIMENTAL
Intervention: GPO-VIR S30(®) [d4T plus lamivudine (3TC) plus nevirapine (NVP)] followed by GPO-VIR Z250(®) [AZT plus 3TC plus NVP]
Number of subjects: 150

Group type: COMPARATOR
Intervention: GPO-VIR Z250(®) [AZT plus 3TC plus NVP]
Number of subjects: 150

Group type: COMPARATOR
Intervention: TDF plus emtricitabine [FTC] plus NVP
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: GPO-VIR S30(®) [d4T plus lamivudine (3TC) plus nevirapine (NVP)]
Number of subjects: 150
Study: 19344076

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg daily for 12 weeks)
Number of subjects: 51
Study: 17942579

Group type: EXPERIMENTAL
Intervention: High sodium intake (250 mmol [5.75 g] per day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Posture change (supine/seated)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low sodium intake (70 mmol [1.61 g] per day)
Number of subjects: 24
Study: 15260834

Group type: EXPERIMENTAL
Intervention: Volunteer-support program for families at risk
Number of subjects: 58

Group type: COMPARATOR
Intervention: Comparison group (assessments only)
Number of subjects: 58
Study: 10811074

Group type: COMPARATOR
Intervention: Observation (no intervention) for 100 eyes
Number of subjects: 224
Study: 8623970

Group type: EXPERIMENTAL
Intervention: 10 mL bupivacaine 0.125% with 50 micrograms fentanyl followed by an infusion of 0.125% bupivacaine and 0.0002% fentanyl at 10 mL/h
Number of subjects: 28

Group type: COMPARATOR
Intervention: 10 mL bupivacaine 0.125% followed by an infusion of 0.125% bupivacaine at 10 mL/h
Number of subjects: 28
Study: 1611229

Group type: EXPERIMENTAL
Intervention: verlukast 8 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: verlukast 2 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 6689975

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (5000 units two hours before operation and then 12-hourly for seven days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Isotonic saline (same regimen as heparin)
Number of subjects: 95
Study: 31168921

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30317965

Group type: EXPERIMENTAL
Intervention: Immediate nonfunctional loading of implants (20 implants)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional loading protocol (19 implants)
Number of subjects: 32
Study: 28076671

Group type: EXPERIMENTAL
Intervention: MOMCare (Brief Interpersonal Psychotherapy and/or antidepressants)
Number of subjects: 164

Group type: COMPARATOR
Intervention: MSS-Plus (intensive public health Maternity Support Services)
Number of subjects: 164
Study: 23006654

Group type: EXPERIMENTAL
Intervention: Spiritual care educational and reflective program based on the Burkhart/Hogan theory of spiritual care in nursing practice, incorporating face‐to‐face and on‐line components
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Spiritual care educational and reflective program
Number of subjects: 59
Study: 19657182

Group type: EXPERIMENTAL
Intervention: Enhanced tinnitus retraining therapy (TRT) including Jacobson's progressive muscle relaxation, physiotherapy, education via lectures, training of selective attention, and changes in appraisal, mental attitude, and behavior towards tinnitus.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group (C)
Number of subjects: 0
Study: 18286416

Group type: EXPERIMENTAL
Intervention: Change detection task with familiar scenes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change detection task with unfamiliar scenes
Number of subjects: 0
Study: 16171663

Group type: EXPERIMENTAL
Intervention: General anesthesia (group GA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spinal anesthesia (group S)
Number of subjects: 60
Study: 12589479

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (acute effect)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Resting state (control)
Number of subjects: 10
Study: 10788964

Group type: EXPERIMENTAL
Intervention: Mivacurium (0.2 mg.kg‐1)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Succinylcholine (1.5 mg.kg‐1)
Number of subjects: 94
Study: 8794502

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate (FD) dosage reduction
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no FD dosage reduction)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Substance use group
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Substance use history
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 37
Study: 1524625

Group type: EXPERIMENTAL
Intervention: Bronchoretard (theophylline sustained-release preparation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diffumal (theophylline formulation of large consumption)
Number of subjects: 0
Study: 2867023

Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg nocte
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pirenzepine 150 mg nocte
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30040033

Group type: EXPERIMENTAL
Intervention: BFR‐RE (15 repetitions; 30% 1‐repetition maximum)
Number of subjects: 12

Group type: COMPARATOR
Intervention: HI‐RE (80% 1‐repetition maximum to muscular failure)
Number of subjects: 12

Group type: COMPARATOR
Intervention: LI‐RE (30% 1‐repetition maximum to muscular failure)
Number of subjects: 12
Study: 29635534

Group type: EXPERIMENTAL
Intervention: Heparinoid moisturizer for prophylaxis (group P)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No moisturizer (group C)
Number of subjects: 0
Study: 27009314

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IV cannulation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard IV cannulation
Number of subjects: 61
Study: 24479642

Group type: EXPERIMENTAL
Intervention: Unsupervised whole body vibration (WBV) training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Supervised multi-purpose exercise (MG)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Multi-purpose exercise with vibration (VMG)
Number of subjects: 54
Study: 22333567

Group type: EXPERIMENTAL
Intervention: Proximal tibiofibular joint manipulation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Distal tibiofibular joint manipulation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 20347164

Group type: EXPERIMENTAL
Intervention: English version of the questionnaire
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: French version of the questionnaire
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Test-retest method for repeatability
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Validity assessment using on-farm observations
Number of subjects: 112
Study: 18634442

Group type: EXPERIMENTAL
Intervention: Eviprostat tablet (6 tabs/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVI-F tablet (3 tabs/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 0
Study: 17920256

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg daily
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study: 15197114

Group type: EXPERIMENTAL
Intervention: A-line ARX index (AAI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bispectral index (BIS)
Number of subjects: 80
Study: 11393438

Group type: EXPERIMENTAL
Intervention: Data-driven assessor training
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Schema-driven assessor training
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control training
Number of subjects: 390
Study: 9589354

Group type: EXPERIMENTAL
Intervention: High-risk women with cytologic evidence of hyperplasia with or without atypia
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: High-risk women with aneuploidy and overexpression of biomarkers (EGFR, p53)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: High-risk women with overexpression of ER and HER-2/neu
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: High-risk women with normal cytology, epithelial hyperplasia, and hyperplasia with atypia
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Later detection of neoplastic conditions
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Number of biomarker abnormalities in the 3-test battery
Number of subjects: 254
Study: 7920882

Group type: EXPERIMENTAL
Intervention: GnRH/TRH stimulation tests in early follicular phase (EFP) and midluteal phase (MLP)
Number of subjects: 40
Study: 2980548

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 100

Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 100
Study: 11480601

Group type: EXPERIMENTAL
Intervention: Flat polyethylene insert (20 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Concave polyethylene insert (20 patients)
Number of subjects: 40
Study: 30711862

Group type: EXPERIMENTAL
Intervention: Prebiotic group (n=70)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Non-prebiotic group (n=70)
Number of subjects: 140
Study: 30230531

Group type: EXPERIMENTAL
Intervention: PRISM intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 92
Study: 27377782

Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 20
Study: 24687229

Group type: EXPERIMENTAL
Intervention: Reading comprehension strategy prompts integrated into digital text
Number of subjects: 15

Group type: COMPARATOR
Intervention: No strategy prompt condition
Number of subjects: 15
Study: 22229256

Group type: EXPERIMENTAL
Intervention: Oral letrozole (2.5 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Subcutaneous gonadotropin-releasing hormone agonist (goserelin, 3.6 mg)
Number of subjects: 32
Study: 20452196

Group type: EXPERIMENTAL
Intervention: SFC250 (salmeterol/fluticasone propionate combination 50/250 microg bd)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: SFC500 (salmeterol/fluticasone propionate combination 50/500 microg bd)
Number of subjects: 178

Group type: COMPARATOR
Intervention: SFC250
Number of subjects: 178

Group type: COMPARATOR
Intervention: SFC500
Number of subjects: 178
Study: 17592691

Group type: EXPERIMENTAL
Intervention: Supported discharge (home treatment)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional in-patient care
Number of subjects: 44
Study: 15651051

Group type: EXPERIMENTAL
Intervention: Sodium valproate (1000 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lithium (900 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 12003257

Group type: EXPERIMENTAL
Intervention: Plant sterol-enriched spread (8.3% sterol content, 25 g/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control spread (35% fat, similar fat composition)
Number of subjects: 42
Study: 10411835

Group type: EXPERIMENTAL
Intervention: Marshall‐Marchetti‐Krantz urethropexy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Burch colposuspension
Number of subjects: 30
Study: 7486351

Group type: EXPERIMENTAL
Intervention: Virtual world training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Real world training
Number of subjects: 0
Study: 2181689

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 68

Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 68
Study: 381873

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 31433396

Group type: EXPERIMENTAL
Intervention: Pyrophosphate-based mouth rinse (B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo mouth rinse (A)
Number of subjects: 40
Study: 30139208

Group type: EXPERIMENTAL
Intervention: Graduated within the previous 10 years
Number of subjects: 200

Group type: COMPARATOR
Intervention: Graduated between 10 and 20 years
Number of subjects: 200

Group type: COMPARATOR
Intervention: Graduated more than 20 years ago
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall knowledge score
Number of subjects: 200
Study: 25888662

Group type: EXPERIMENTAL
Intervention: Pelvic floor strengthening exercises with electrotherapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pelvic floor strengthening exercises without electrotherapy (control group)
Number of subjects: 24
Study: 25154778

Group type: EXPERIMENTAL
Intervention: Fortified rice (cold and hot extruded)
Number of subjects: 2011

Group type: COMPARATOR
Intervention: Conventional rice
Number of subjects: 2011
Study: 22799613

Group type: EXPERIMENTAL
Intervention: Triple-combination treatment (OM 40 mg/AML 10 mg/HCTZ 25 mg)
Number of subjects: 2492

Group type: COMPARATOR
Intervention: Dual-combination treatments (OM 40 mg/AML 10 mg, OM 40 mg/HCTZ 25 mg, or AML 10 mg/HCTZ 25 mg)
Number of subjects: 2492
Study: 20173299

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17278987

Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril-based therapy, with possible addition of indapamide)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study: 15644658

Group type: EXPERIMENTAL
Intervention: Sedation algorithm (algorithm group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 102